Login Register Cart 0
Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Investigating the Mechanism of Banxia Xiexin Decoction in Treating Gastritis and Diabetes Mellitus through Network Pharmacology and Molecular Docking Analysis

Author(s): Yikuan Du, Xianhong Chi, Qianwen Chen, Yue Xiao, Zhendong Ma, Zhenjie Wang, Zhuoming Guo, Peng Chen, Zilin Chen, Mengting Zhang, Jinyan Guo, Yuqi Zhou and Chun Yang*

Volume 19, Issue 7, 2024

Published on: 18 April, 2024

Page: [878 - 897] Pages: 20

DOI: 10.2174/0115748855287070240409061220

Price: $65

Abstract

Background: Banxia Xiexin Decoction (BXD), a complex prescription in Traditional Chinese Medicine (TCM), clinically acts as a treatment for gastritis and diabetes while its mechanism of treatment remains unknown.

Objectives: This study aimed to explore the common mechanism of BXD in treating gastritis and diabetes based on network pharmacology and molecular docking technology.

Methods: The seven Chinese herbal components and drug targets were collected from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) for gastritis and diabetes using GeneCards, DisGeNET, Comparative Toxicogenomics Database (CTD), and Online Mendelian Inheritance in Man (OMIM) databases. Common drug and disease targets were imported into the STRING data platform for protein-protein interaction (PPI) analysis, and Cytoscape 3.7.2 software for network topology analysis, and core targets were filtered.

Results: There were 124 components, 249 targets, 449 targets for gastritis, and 4005 targets for diabetes. After mapping, 83 BXD targets for gastritis and diabetes were obtained, and the targets with high correlation were STAT 3, JUN, TNF, IL-6, etc. More relevant targets were involved in the cancer pathway, AGE-RAGE signaling pathway of diabetic complications, fluid shear stress, and atherosclerosis pathway.

Conclusion: This study preliminarily reveals that BXD may play a role in the treatment of gastritis and diabetes mellitus through multi-components, multi-targets, and multi-pathways, and proposes some potential "component-target-pathway" hypotheses in light of previous reports.

« Previous Next »
Graphical Abstract

[1]
Schleicher E, Gerdes C, Petersmann A. Definition, classification and diagnosis of diabetes mellitus. Exp Clin Endocrinol Diabetes 2022; 130(S 01): S1-8.
[http://dx.doi.org/10.1055/a-1624-2897] [PMID: 35451038]
[2]
Williams R, Karuranga S, Malanda B. Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 2020; 162: 108072.
[http://dx.doi.org/10.1016/j.diabres.2020.108072]
[3]
Sun J, Ren J, Hu X, Hou Y, Yang Y. Therapeutic effects of Chinese herbal medicines and their extracts on diabetes. Biomed Pharmacother 2021; 142: 111977.
[http://dx.doi.org/10.1016/j.biopha.2021.111977] [PMID: 34364042]
[4]
Liu S, Deng Z, Zhu J, et al. Gastric immune homeostasis imbalance: An important factor in the development of gastric mucosal diseases. Biomed Pharmacother 2023; 161: 114338.
[http://dx.doi.org/10.1016/j.biopha.2023.114338] [PMID: 36905807]
[5]
Xie W. Clinical characteristics of patients with different types of chronic gastritis and identification and treatment in Chinese medicine. Chronic Pathematology Journal 2021; 22(06): 918-9.
[http://dx.doi.org/10.16440/j.cnki.1674-8166.2021.06.031]
[6]
Chen L, Wei S, He Y, et al. Treatment of chronic gastritis with traditional chinese medicine: Pharmacological Activities and mechanisms. Pharmaceuticals (Basel) 2023; 16(9): 1308.
[http://dx.doi.org/10.3390/ph16091308] [PMID: 37765116]
[7]
Ren B. Prevalence and risk factors of gastritis disease in patients with type 2 diabetes. J Prev Med Chin PLA 2017; 35(02): 137-8.
[http://dx.doi.org/10.13704/j.cnki.jyyx.2017.02.013]
[8]
Shah SC, Piazuelo MB, Kuipers EJ, Li D. AGA clinical practice update on the diagnosis and management of atrophic gastritis: Expert review. Gastroenterology 2021; 161(4): 1325-1332.e7.
[http://dx.doi.org/10.1053/j.gastro.2021.06.078] [PMID: 34454714]
[9]
Tong X, Liu X, Wu J. Diabetes prevention and control guidelines for chinese medicine. Chinese Med Modern Dis Edu China 2011; 9(04): 148-51.
[10]
Zhang S, Tang X, Huang S. Expert consensus opinion on the diagnosis and treatment of chronic gastritis in Chinese medicine. China J Tradit Chin Med Pharm 2017; 32(07): 3060-4.
[11]
Wang W, Gu W, He C, Zhang T, Shen Y, Pu Y. Bioactive components of Banxia Xiexin Decoction for the treatment of gastrointestinal diseases based on flavor-oriented analysis. J Ethnopharmacol 2022; 291: 115085.
[http://dx.doi.org/10.1016/j.jep.2022.115085] [PMID: 35150814]
[12]
Ni J, Xu X, Song P. Effectiveness of Han Xia Di Xuan Xin Tang plus reduction in the treatment of (spleen deficiency and stomach stagnation evidence) type 2 diabetes mellitus and the effect on its TCM evidence score and blood glucose level. Diabetes New World 2022; 25(18): 20-3.
[http://dx.doi.org/10.16658/j.cnki.1672-4062.2022.18.020]
[13]
Tian J, Qin X. Application of network pharmacology in study of “the same disease with differenttreatments” and “different diseases with the same treatment” of traditional Chinese medicine. Chinese Journal of Pharmacology and Toxicology 2018; 32(11): 861-2.
[14]
Liu D, Liu M, Liu X. Pharmacological mechanism of Gubi Fang in treating knee osteoarthritis based on network pharmacology. Traditional Chinese Drug Research and Clinical Pharmacology 2020; 31(03): 306-14.
[http://dx.doi.org/10.19378/j.issn.1003-9783.2020.03.010]
[15]
Gao Q, Tian D, Han Z, et al. Network Pharmacology and molecular docking analysis on molecular targets and mechanisms of Buyang Huanwu decoction in the treatment of ischemic stroke. Evid Based Complement Alternat Med 2021; 2021: 8815447.
[http://dx.doi.org/10.1155/2021/8815447] [PMID: 33727944]
[16]
He X, Wang X. Effect of qi-invigorating blood-activating decoration on blood rheology and renal function in diabetic patients. J Chin Med Mater 2017; 40(04): 957-9.
[17]
He L, Wang H, Gu C, He X, Zhao L, Tong X. Administration of traditional chinese blood circulation activating drugs for microvascular complications in patients with Type 2 diabetes mellitus. J Diabetes Res 2016; 2016: 1081657.
[http://dx.doi.org/10.1155/2016/1081657] [PMID: 27830156]
[18]
Zhang S, Li Q, Huang S. Consensus opinion on the treatment of chronic superficial gastritis in Chinese medicine (2009, Shenzhen). Chin J Integr Tradit West Med Dig 2010; 18(3): 207-9.
[19]
Dai X, Ding Y, Zhang Z. Quercetin but not quercitrin ameliorates tumor necrosis factor-alpha-induced insulin resistance in C2C12 skeletal muscle cells. Biol Pharm Bull 2013; 36(5): 788-95.
[http://dx.doi.org/10.1248/bpb.b12-00947] [PMID: 23439570]
[20]
Zhang S, Huang J, Xie X, He Y, Mo F, Luo Z. Quercetin from polygonum capitatum protects against gastric inflammation and apoptosis associated with helicobacter pylori infection by affecting the levels of p38MAPK, BCL-2 and BAX. Molecules 2017; 22(5): 744.
[http://dx.doi.org/10.3390/molecules22050744] [PMID: 28481232]
[21]
Shi GJ, Li Y, Cao QH, et al. In vitro and in vivo evidence that quercetin protects against diabetes and its complications: A systematic review of the literature. Biomed Pharmacother 2019; 109: 1085-99.
[http://dx.doi.org/10.1016/j.biopha.2018.10.130] [PMID: 30551359]
[22]
Chen S, Jiang H, Wu X, Fang J. Therapeutic effects of quercetin on inflammation, obesity, and Type 2 Diabetes. Mediators Inflamm 2016; 2016: 9340637.
[http://dx.doi.org/10.1155/2016/9340637] [PMID: 28003714]
[23]
Guo X, Ruan Y, Li Z, Li D. Flavonoid subclasses and type 2 diabetes mellitus risk: A meta-analysis of prospective cohort studies. Crit Rev Food Sci Nutr 2019; 59(17): 2850-62.
[http://dx.doi.org/10.1080/10408398.2018.1476964] [PMID: 29768032]
[24]
Luo C, Yang H, Tang C, et al. Kaempferol alleviates insulin resistance via hepatic IKK/NF-κB signal in type 2 diabetic rats. Int Immunopharmacol 2015; 28(1): 744-50.
[http://dx.doi.org/10.1016/j.intimp.2015.07.018] [PMID: 26263168]
[25]
Jeong HY, Sung GH, Kim JH, et al. Syk and Src are major pharmacological targets of a Cerbera manghas methanol extract with kaempferol-based anti-inflammatory activity. J Ethnopharmacol 2014; 151(2): 960-9.
[http://dx.doi.org/10.1016/j.jep.2013.12.009] [PMID: 24342777]
[26]
Zhang HL, You LM, Liu H, et al. Wogonin-mediated inhibition of LPS and ATP-induced inflammation in mousemacrophages. Chinese Journal of Immunology 2019; 35(09): 1059-63.
[27]
Marcelino G, Machate DJ, Freitas KC, et al. β-Carotene: Preventive role for Type 2 Diabetes Mellitus and Obesity: A review. Molecules 2020; 25(24): 5803.
[http://dx.doi.org/10.3390/molecules25245803] [PMID: 33316948]
[28]
Salminen A, Kaarniranta K, Kauppinen A. Insulin/IGF-1 signaling promotes immunosuppression via the STAT3 pathway: Impact on the aging process and age-related diseases. Inflamm Res 2021; 70(10-12): 1043-61.
[http://dx.doi.org/10.1007/s00011-021-01498-3] [PMID: 34476533]
[29]
Balic JJ, Saad MI, Dawson R, et al. Constitutive STAT3 serine phosphorylation promotes helicobacter-mediated gastric disease. Am J Pathol 2020; 190(6): 1256-70.
[http://dx.doi.org/10.1016/j.ajpath.2020.01.021] [PMID: 32201262]
[30]
Gao Z, Wang G, Ma X, et al. Troxerutin attenuates insulin resistance via pancreatic IL-22/JAK1/STAT3 signaling activation in dihydrotestosterone-induced polycystic ovary syndrome rats. Am J Physiol Endocrinol Metab 2022; 323(5): E405-17.
[http://dx.doi.org/10.1152/ajpendo.00150.2022] [PMID: 36103628]
[31]
Zhang L, Chen Z, Wang Y, Tweardy DJ, Mitch WE. Stat3 activation induces insulin resistance via a muscle-specific E3 ubiquitin ligase Fbxo40. Am J Physiol Endocrinol Metab 2020; 318(5): E625-35.
[http://dx.doi.org/10.1152/ajpendo.00480.2019] [PMID: 32101031]
[32]
Jayaraman S, Devarajan N, Rajagopal P, et al. β-Sitosterol circumvents obesity induced inflammation and insulin resistance by down-regulating IKKβ/NF-κB and JNK signaling pathway in adipocytes of Type 2 Diabetic Rats. Molecules 2021; 26(7): 2101.
[http://dx.doi.org/10.3390/molecules26072101] [PMID: 33917607]
[33]
Mitsuyama K, Tsuruta O, Matsui Y, et al. Activation of c-Jun Nterminal kinase (JNK) signalling in experimentally induced gastric lesions in rats. Clin Exp Immunol 2006; 143(1): 24-9.
[34]
Shi Y, Ning J, Norbu K, et al. The tibetan medicine Zuozhu-Daxi can prevent Helicobacter pylori induced-gastric mucosa inflammation by inhibiting lipid metabolism. Chin Med 2022; 17(1): 126.
[http://dx.doi.org/10.1186/s13020-022-00682-9] [PMID: 36348469]
[35]
Zhao CN, Xiao LL, Zhang Y. Effects of Helicobacter pylori infection on the prognosis of chronic atrophic gastritis by inducing the macrophage polarization. Gastroenterol Res 2023; 16(4): 226-33.
[http://dx.doi.org/10.14740/gr1636] [PMID: 37691749]
[36]
Wu G, Bai Z, Wan Y, Shi H, Huang X, Nie S. Antidiabetic effects of polysaccharide from azuki bean (Vigna angularis) in type 2 diabetic rats via insulin/PI3K/AKT signaling pathway. Food Hydrocoll 2020; 101: 105456.
[http://dx.doi.org/10.1016/j.foodhyd.2019.105456]
[37]
Oh J, Cho JY, Kim D. Hyptis obtusiflora C. Presl ex benth methanolic extract exhibits anti-inflammatory and anti-gastritis activities via suppressing AKT/NF-κB pathway. Plants 2023; 12(5): 1146.
[http://dx.doi.org/10.3390/plants12051146] [PMID: 36904006]
[38]
Twarda-Clapa A, Olczak A, Białkowska AM, Koziołkiewicz M. Advanced Glycation End-Products (AGEs): Formation, Chemistry, Classification, Receptors, and Diseases Related to AGEs. Cells 2022; 11(8): 1312.
[http://dx.doi.org/10.3390/cells11081312] [PMID: 35455991]
[39]
Snelson M, Lucut E, Coughlan MT. The Role of AGE-RAGE signalling as a modulator of gut permeability in diabetes. Int J Mol Sci 2022; 23(3): 1766.
[http://dx.doi.org/10.3390/ijms23031766] [PMID: 35163688]
[40]
Kong WJ, Li YH, Jiang JD. Biological principles for “homotherapy for heteropathy”. J Pharm 2024; 59(02): 269-78.
[http://dx.doi.org/10.16438/j.0513-4870.2023-1103]
[41]
Sun Y, Jin C, Zhang X, Jia W, Le J, Ye J. Restoration of GLP-1 secretion by Berberine is associated with protection of colon enterocytes from mitochondrial overheating in diet-induced obese mice. Nutr Diabetes 2018; 8(1): 53.
[http://dx.doi.org/10.1038/s41387-018-0061-x] [PMID: 30250193]
[42]
Li J, Meng P, Zhang J, He M. Effect of berberine hydrochloride on the diversity of intestinal flora in Parkinson’s Disease patients. Contrast Media Mol Imaging 2022; 2022: 8381870.
[http://dx.doi.org/10.1155/2022/8381870] [PMID: 35685661]
[43]
Perrone A, Giovino A, Benny J, Martinelli F. Advanced Glycation End Products (AGEs): Biochemistry, signaling, analytical methods, and epigenetic effects. Oxid Med Cell Longev 2020; 2020: 3818196.
[http://dx.doi.org/10.1155/2020/3818196] [PMID: 32256950]
[44]
Khalid M, Petroianu G, Adem A. Advanced glycation end products and diabetes mellitus: Mechanisms and perspectives. Biomolecules 2022; 12(4): 542.
[http://dx.doi.org/10.3390/biom12040542] [PMID: 35454131]
[45]
Nandipati KC, Subramanian S, Agrawal DK. Protein kinases: Mechanisms and downstream targets in inflammation-mediated obesity and insulin resistance. Mol Cell Biochem 2017; 426(1-2): 27-45.
[http://dx.doi.org/10.1007/s11010-016-2878-8] [PMID: 27868170]
[46]
Ragazzi E, Burlina S, Cosma C, Chilelli NC, Lapolla A, Sartore G. Anti-diabetic combination therapy with pioglitazone or glimepiride added to metformin on the AGE-RAGE axis: A randomized prospective study. Front Endocrinol (Lausanne) 2023; 14: 1163554.
[http://dx.doi.org/10.3389/fendo.2023.1163554] [PMID: 37635976]
[47]
Dorenkamp M, Nasiry M, Semo D, et al. Pharmacological targeting of the RAGE-NFκB signalling axis impedes monocyte activation under diabetic conditions through the repression of shp-2 tyrosine phosphatase function. Cells 2023; 12(3): 513.
[http://dx.doi.org/10.3390/cells12030513] [PMID: 36766855]
[48]
Kamioka M, Ishibashi T, Sugimoto K, et al. Blockade of renin-angiotensin system attenuates advanced glycation end products-mediated signaling pathways. J Atheroscler Thromb 2010; 17(6): 590-600.
[http://dx.doi.org/10.5551/jat.3624] [PMID: 20379053]
[49]
Uribarri J, del Castillo MD, de la Maza MP, et al. Dietary advanced glycation end products and their role in health and disease. Adv Nutr 2015; 6(4): 461-73.
[http://dx.doi.org/10.3945/an.115.008433] [PMID: 26178030]
[50]
Huang H, Xiao F, Jia H. Protection of beta-cell function by miR-138-5p through regulation of hypoxia-inducible factor 1α in patients with gestational diabetes. Chin J Clin Pharmacol Ther 2020; 25(05): 489-97.
[http://dx.doi.org/10.12092/j.issn.1009-2501.2020.05.002]
[51]
Wang K, Ma L, Wang H, Tang CZ, Huang DY. Acupoint catgut embedding improves gastric mucosal injury by down-regulating expression of HlF-1a and VEGF in chronic atrophic gastritis rats. Acupuncture Research 2020; 45(5): 384-8.
[http://dx.doi.org/10.13702/j.1000-0607.190189] [PMID: 32447853]
[52]
Li XR, Guo QL, Lu N. Researching Progress in the Pathway Acting on Vascular Endothelial Cells of VEGFR2and its Signaling lnhibitors. Pharmaceutical Biotechnology 2016; 23(03): 274-8.
[http://dx.doi.org/10.19526/j.cnki.1005-8915.2016.03.019]
[53]
Hou Y, Lin M, Mei W. Effect of wogonin on diabetic retinopathy in type 2 diabetic mice. Archives of Traditional Chinese Medicine 2019; 37(10): 2398-400.
[http://dx.doi.org/10.13193/j.issn.1673-7717.2019.10021]
[54]
Wang S, Li Y, Yuan T. Effect of wogonin on proliferation inhibition and energy metabolism of SGC-7901 cells and ECV304 cells. Traditional Chinese Drug Research and Clinical Pharmacology 2019; 30(12): 1428-33.
[http://dx.doi.org/10.19378/j.issn.1003-9783.2019.12.004]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy